The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.
Katrin Marie Sjoquist
No relevant relationships to disclose
Dirkje Willemien Sommeijer
No relevant relationships to disclose
Janine Margaret Lombard
No relevant relationships to disclose
Linda R. Mileshkin
No relevant relationships to disclose
Philip James Beale
No relevant relationships to disclose
Peter T. Grant
No relevant relationships to disclose
Penny Blomfield
No relevant relationships to disclose
Michael Quinn
No relevant relationships to disclose
Alison Maree Hadley
No relevant relationships to disclose
Peter Sykes
No relevant relationships to disclose
Yoland Catherine Antill
No relevant relationships to disclose
Rachel O'Connell
No relevant relationships to disclose
Julie Martyn
No relevant relationships to disclose
Kim Gillies
No relevant relationships to disclose
David Cannan
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Martin R. Stockler
No relevant relationships to disclose
Richard J Edmondson
No relevant relationships to disclose
Frederic Amant
No relevant relationships to disclose
Michael Friedlander
No relevant relationships to disclose